Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a...
Related Questions
How does the efficacy (average 27.3 lb weight loss) of orforglipron compare to existing GLP‑1 products like Wegovy or Mounjaro?
How sensitive is the stock to any upcoming data releases or updates from the ATTAIN‑2 trial?
What potential partnership or licensing opportunities could arise from this oral GLP‑1 platform?
Could the oral formulation create a competitive advantage in patient adherence versus injectables?
How will the Phase 3 results impact Eli Lilly's (LLY) stock valuation in the short term?
What pricing strategy is likely for an oral GLP‑1 therapy and how will it affect profit margins?
Will the safety and tolerability profile raise any regulatory or reimbursement concerns?
What is the expected market size for an oral GLP‑1 obesity treatment compared to injectable competitors?
How might the trial results influence analyst coverage and earnings forecasts for Eli Lilly?
What is the projected timeline for FDA approval and commercial launch after the pivotal trials?